Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. PRYMY
5. EXC
6. SKA-B
7. PBA
8. CCH:LN
9. META
10. BAJAJHFL:I

Go back to Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma

FBR Capital Reiterates Outperform on Cerus (CERS) Following FDA Approval

March 16, 2016 10:18 AM EDT

FBR Capital reiterated an Outperform rating and $10.00 price target on Cerus (NASDAQ: CERS) following the FDA's approval of INTERCEPT for the treatment of platelets suspended in 100% plasma.

Analyst Thomas Yip commented, "Earlier this morning, Cerus Corporation announced that the FDA has approved INTERCEPT for the... More